Long-Acting Donepezil Depot Injection Shows Promise for Canine Cognitive Dysfunction Treatment
核心洞察
A randomized controlled trial of 32 dogs with canine cognitive dysfunction (搜索) demonstrated that a single intramuscular injection of long-acting donepezil depot significantly improved behavioral scores and reduced serum neurofilament light chain (搜索) levels.
High-dose treatment showed significant improvements in cognitive assessment scales at both 14 and 28 days, while low-dose treatment primarily improved at day 28 with earlier effects limited to one scale.
Both treatment groups had significantly lower serum NfL levels than controls at day 28, with quality-of-life improvements in activity, sociability, and overall condition.
A novel long-acting donepezil depot injection has demonstrated favorable safety and potential efficacy in treating canine cognitive dysfunction (搜索) (CCD), according to a randomized controlled trial published in Frontiers in Veterinary Science. The study of 32 dogs with clinically diagnosed CCD showed significant improvements in behavioral scores and biomarker levels following a single intramuscular injection.
Study Design and Methodology
Researchers from multiple Korean institutions conducted a randomized trial involving 32 dogs with clinically diagnosed CCD. The dogs were randomly assigned to three groups: high-dose treatment (n = 11), low-dose treatment (n = 11), or control (n = 10). Diagnosis was established using the Canine Cognitive Dysfunction (搜索) Rating Scale (CCDR), the CAnine DEmentia Scale (CADES), and DISHAA scoring, with baseline MRI performed in selected dogs with owner consent.
The study evaluated both behavioral outcomes and serum neurofilament light chain (搜索) (NfL) as primary endpoints, with evaluations conducted on days 14 and 28 following a single intramuscular injection administered on day 0.
Treatment Outcomes and Efficacy
The high-dose group demonstrated significant improvements across all three cognitive assessment scales at both 14 and 28 days post-treatment. In contrast, the low-dose group showed improvements primarily at day 28, with earlier effects limited to the CADES scale (p < 0.05).
A key finding was the significant reduction in serum NfL levels observed in both treatment groups compared to controls at day 28 (p < 0.05), while within-group values remained stable throughout the study period. Neurofilament light chain (搜索) serves as a biomarker for neuronal damage and has potential diagnostic value in cognitive dysfunction assessment.
Quality of Life Improvements
Beyond cognitive measures, the study documented improvements in quality-of-life scores across multiple domains. Dogs receiving treatment showed enhanced activity levels, improved sociability, better overall condition, and higher global quality-of-life scores compared to controls.
Safety Profile
The safety evaluation revealed that adverse events were mild and transient across both treatment groups. This favorable safety profile supports the potential clinical application of the long-acting formulation in veterinary practice.
Clinical Significance for Veterinary Medicine
Canine cognitive dysfunction (搜索) represents an age-related neurodegenerative disorder with limited effective treatment options currently available. Unlike human Alzheimer's disease (搜索), objective diagnostic and therapeutic assessment tools using biomarkers or neuroimaging remain underdeveloped for CCD.
The researchers noted that this study highlights the value of integrating clinical and biomarker-based assessments in future CCD management. The combination of behavioral scoring systems with serum NfL measurements provides a more comprehensive approach to evaluating treatment efficacy in this challenging condition.
The long-acting depot formulation offers practical advantages over traditional oral medications, potentially improving treatment compliance and reducing the frequency of veterinary visits required for ongoing management of cognitive dysfunction in aging dogs.